Table 1 Baseline characteristics of the primary cohort and the validation cohort

Age

67(59–74)

70(62–78)

− 1.441^a

0.149

Sex, male

97(74.0)

39(61.9)

2.992

0.084

Admission SBP mmHg

152 ± 21

153 ± 21

−0.260^b

0.796

Admission DBP mmHg

86(78–98)

85(78–92)

−0.378^a

0.705

Admission glucose

5.7(4.9--6.8)

6.1(5.2--7.6)

−1.419^a

0.156

Stroke

24(18.3)

6 (9.5)

2.518

0.113

Smoke

46(35.1)

19(30.2)

0.469

0.493

Dyslipidemia

20(15.3)

11(17.5)

0.152

0.696

Antiplatelets/anticoagulation

20(15.3)

9(14.3)

0.032

0.858

Hypertension

92(70.2)

40(63.5)

0.888

0.346

Diabetes

26(19.8)

18(28.6)

1.846

0.174

Atrial fibrillation

30 (22.9)

21(33.3)

2.389

0.122

CDS score

4.008

0.253

 0

31(23.7)

14(22.2)

 1

60(45.8)

22(34.9)

 2

32(24.4)

24(38.1)

 3

8(6.1)

3(4.8)

NIHSS score

6(3–11)

6(3–12)

−0.219^a

0.827

OTT for thrombolysis min

160(120–200)

183(130–210)

−1.721^a

0.085

Platelet *10^9 /L

181(152–215)

185(147–224)

0.198^a

0.843

LDL mmol/L

2.58 ± 0.77

2.51 ± 0.62

0.626^b

0.532

Creatinine umol/L

70.4(59.9–80.0)

69.9(55.4–84.0)

−0.868^a

0.385

CRP mg/L

3.7(1.7–13.3)

4.6(1.3–10.5)

−0.582^a

0.561

Uric acid mmol/L

300.2(241.0–351.3)

290.4(248.8–351.3)

−0.164^a

0.870

CSVD score

0.575

0.966

 0

23(17.6)

11(17.5)

 1

46(35.1)

24(38.1)

 2

39(29.8)

16(25.4)

 3

18(13.7)

10(15.9)

 4

5(3.8)

2(3.2)

HT after thrombolysis

16(12.2)

6 (9.5)

0.306

0.580